AES 14

Drug Profile

AES 14

Alternative Names: Aesgen-14; E 6014; L-glutamine suspension - Aesgen; Saforis; Uptake-enhanced L-glutamine suspension

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator MGI Pharma
  • Developer Eisai Co Ltd
  • Class Basic amino acids; Diamino amino acids; Neutral amino acids; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Stomatitis

Most Recent Events

  • 15 May 2012 Discontinued - Phase-III for Stomatitis in USA (PO)
  • 01 Nov 2011 Phase III development is ongoing in US
  • 29 Jan 2008 MGI Pharma has been acquired by Eisai
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top